Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 673 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Boehringer Ingelheim Clear all
Completed Phase 1 Interventional Results available

A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours

NCT02952248
View directory record Official record
Conditions
Neoplasms
Interventions
BI 754091
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
7
States / cities
Sarasota, Florida • Harvey, Illinois • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes

NCT01734785
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Linagliptin, Empagliflozin + Linagliptin, Empagliflozin placebo + Linagliptin placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
28
States / cities
Gulf Shores, Alabama • Norwalk, California • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 9:14 PM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

NCT00681863
View directory record Official record
Conditions
Tourette Syndrome
Interventions
pramipexole 0.125 mg BID, pramipexole 0.0625 mg QD, pramipexole 0.125 mg TID, pramipexole 0.25 mg BID, pramipexole 0.0625 mg BID
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
13
States / cities
Bradenton, Florida • Tampa, Florida • Columbus, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 23, 2014 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis

NCT02597933
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Nintedanib, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)

NCT03057977
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
3,730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
92
States / cities
La Mesa, California • Long Beach, California • Los Angeles, California + 81 more
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 15, 2026, 9:14 PM EDT
Terminated Phase 2 Interventional Results available

Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]

NCT02780700
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
Nintedanib, Capecitabine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension

NCT00881530
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Metformin, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer

NCT02776683
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
BI 695502, Avastin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Anaheim, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Not applicable Interventional Results available

Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure

NCT04394754
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
BodyPort, Noom, Conversa
Device · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 79 Years
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Oct 15, 2026, 9:14 PM EDT
Completed No phase listed Observational

Describing Patient With DME, Their Patient Journey and Disease Progression

NCT05966753
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
221,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 15, 2026, 9:14 PM EDT
Withdrawn Phase 1 Interventional

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

NCT02905994
View directory record Official record
Conditions
AML
Interventions
Volasertib, Cytarabine, Idarubicin, Bone Marrow Biopsy
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 15, 2026, 9:14 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

NCT06013969
View directory record Official record
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Irvine, California • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

NCT06962839
View directory record Official record
Conditions
Macular Edema
Interventions
BI 1815368, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
36
States / cities
Phoenix, Arizona • Arcadia, California • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment

NCT01164501
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Renal Insufficiency
Interventions
BI 10773, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
18
States / cities
Anaheim, California • Lomita, California • Plantation, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Oct 15, 2026, 9:14 PM EDT
Recruiting Phase 3 Interventional

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

NCT07220083
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis
Interventions
BI 764198, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
77
States / cities
Alabaster, Alabama • Huntsville, Alabama • Surprise, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Terminated Phase 1 Interventional Results available

Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).

NCT02009761
View directory record Official record
Conditions
Purpura, Thrombocytopenic, Idiopathic
Interventions
BI 655064
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test How Well BI 1291583 is Tolerated by People With Cystic Fibrosis Bronchiectasis (Clairafly™)

NCT05865886
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis
Interventions
BI 1291583, Placebo to BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
7
States / cities
Denver, Colorado • Altamonte Springs, Florida • South Portland, Maine + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 2 Interventional

A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT06335303
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
BI 1819479, Placebo matching BI 1819479
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Lakewood, Colorado • Kissimmee, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 1 Interventional

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

NCT06692322
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
Zongertinib (BI 1810631)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain

NCT01929031
View directory record Official record
Conditions
Pain, Postoperative, Tooth Diseases
Interventions
ibuprofen + caffeine, ibuprofen, caffeine, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 55 Years
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 16, 2016 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD)

NCT00400153
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Atrovent Respimat (20 mcg), COMBIVENT MDI (36/206 mcg), Combivent Respimat (20 mcg/100 mcg), Placebo via corresponding inhaler for blinding purposes
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
87
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 74 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2014 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 2 Interventional Results available

BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis

NCT03648541
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Spesolimab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
8
States / cities
Hamden, Connecticut • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 15, 2026, 9:14 PM EDT
Completed Phase 3 Interventional Results available

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

NCT01125566
View directory record Official record
Conditions
Breast Neoplasms
Interventions
BIBW 2992, trastuzumab, vinorelbine
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
14
States / cities
Birmingham, Alabama • Chandler, Arizona • Fountain Valley, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Oct 15, 2026, 9:14 PM EDT